Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations
Issued Date
2022-12-01
Resource Type
ISSN
15257304
eISSN
19380690
Scopus ID
2-s2.0-85138556009
Pubmed ID
36151006
Journal Title
Clinical Lung Cancer
Volume
23
Issue
8
Start Page
670
End Page
685
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical Lung Cancer Vol.23 No.8 (2022) , 670-685
Suggested Citation
Ahn M.J., Mendoza M.J.L., Pavlakis N., Kato T., Soo R.A., Kim D.W., Liam C.K., Hsia T.C., Lee C.K., Reungwetwattana T., Geater S., Chan O.S.H., Prasongsook N., Solomon B.J., Nguyen T.T.H., Kozuki T., Yang J.C.H., Wu Y.L., Mok T.S.K., Tan D.S.W., Yatabe Y. Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations. Clinical Lung Cancer Vol.23 No.8 (2022) , 670-685. 685. doi:10.1016/j.cllc.2022.07.012 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/83528
Title
Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations
Author's Affiliation
National Hospital Organization Shikoku Cancer Center
National Taiwan University Hospital
St. Luke's Medical Center Quezon City
Guangdong General Hospital
Peter Maccallum Cancer Centre
China Medical University Hospital
National Cancer Centre, Singapore
Universiti Malaya
The University of Sydney
National Cancer Center Hospital
Kanagawa Cancer Center Research Institute
SKKU School of Medicine
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Prince of Songkla University
Chinese University of Hong Kong
Seoul National University College of Medicine
Phramongkutklao Hospital
National University Cancer Institute Singapore
Hong Kong Integrated Oncology Centre
National Cancer Hospital
National Taiwan University Hospital
St. Luke's Medical Center Quezon City
Guangdong General Hospital
Peter Maccallum Cancer Centre
China Medical University Hospital
National Cancer Centre, Singapore
Universiti Malaya
The University of Sydney
National Cancer Center Hospital
Kanagawa Cancer Center Research Institute
SKKU School of Medicine
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Prince of Songkla University
Chinese University of Hong Kong
Seoul National University College of Medicine
Phramongkutklao Hospital
National University Cancer Institute Singapore
Hong Kong Integrated Oncology Centre
National Cancer Hospital
Other Contributor(s)
Abstract
Non-small cell lung cancer (NSCLC) is a heterogeneous disease, with many oncogenic driver mutations, including de novo mutations in the Mesenchymal Epithelial Transition (MET) gene (specifically in Exon 14 [ex14]), that lead to tumourigenesis. Acquired alterations in the MET gene, specifically MET amplification is also associated with the development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance in patients with EGFR-mutant NSCLC. Although MET has become an actionable biomarker with the availability of MET-specific inhibitors in selected countries, there is differential accessibility to diagnostic platforms and targeted therapies across countries in Asia-Pacific (APAC). The Asian Thoracic Oncology Research Group (ATORG), an interdisciplinary group of experts from Australia, Hong Kong, Japan, Korea, Mainland China, Malaysia, the Philippines, Singapore, Taiwan, Thailand and Vietnam, discussed testing for MET alterations and considerations for using MET-specific inhibitors at a consensus meeting in January 2022, and in subsequent offline consultation. Consensus recommendations are provided by the ATORG group to address the unmet need for standardised approaches to diagnosing MET alterations in NSCLC and for using these therapies. MET inhibitors may be considered for first-line or second or subsequent lines of treatment for patients with advanced and metastatic NSCLC harbouring MET ex14 skipping mutations; MET ex14 testing is preferred within multi-gene panels for detecting targetable driver mutations in NSCLC. For patients with EGFR-mutant NSCLC and MET amplification leading to EGFR TKI resistance, enrolment in combination trials of EGFR TKIs and MET inhibitors is encouraged.